natgillin/translations-raw huggingface dataset:
By letter dated 10 December 2008, the Finnish Government requested authorisation, for the years 2009-2010, to grant farmers aid for certain quantities of varieties of seeds and cereal seed produced solely in Finland because of its specific climatic conditions.
Z dopisom z dne 10. decembra 2008 je finska vlada zaprosila za dovoljenje, da lahko za leti 2009–2010 kmetom odobri pomoč za določene količine sort semen in semen žit, ki se zaradi posebnih podnebnih razmer pridelujejo samo na Finskem.
In accordance with the second subparagraph of Article 182(2) of Regulation (EC) No 1234/2007, Finland has transmitted to the Commission a satisfactory report on the results of the aid authorised.
V skladu z drugim pododstavkom člena 182(2) Uredbe (ES) št. 1234/2007 je Finska Komisiji predložila zadovoljivo poročilo o rezultatih odobrene pomoči.
By consequence a national aid for cultivated seeds in 2009 may be granted.
Posledično se lahko državna pomoč odobri za semena, gojena v letu 2009.
Finland requests authorisation to grant aid per hectare for certain areas under Gramineae (grass) and Leguminosae (legumes) seeds species as listed in Annex XIII to Council Regulation (EC) No 73/2009 of 19 January 2009 establishing common rules for direct support schemes for farmers under the common agricultural policy and establishing certain support schemes for farmers, amending Regulations (EC) No 1290/2005, (EC) No 247/2006, (EC) No 378/2007 and repealing Regulation (EC) No 1782/2003 [2], with the exception of Phleum pratense L. (Timothy), and for certain areas under cereal seed.
Finska prosi za dovoljenje za odobritev pomoči na hektar za določena območja, zasajena s semeni vrst Gramineae (trave) in Leguminosae (stročnice) iz Priloge XIII k Uredbi Sveta (ES) št. 73/2009 z dne 19. januarja 2009 o skupnih pravilih za sheme neposrednih podpor za kmete v okviru skupne kmetijske politike in o uvedbi nekaterih shem podpor za kmete, spremembi uredb (ES) št. 1290/2005, (ES) št. 247/2006, (ES) št. 378/2007 in razveljavitvi Uredbe (ES) št. 1782/2003 [2], razen Phleum pratense L. (mačji rep), in za določena območja, zasajena s semeni žit.
The proposed aid has to meet the requirements laid down in Article 182(2) of Regulation (EC) No 1234/2007.
Predlagana pomoč mora izpolnjevati zahteve iz člena 182(2) Uredbe (ES) št. 1234/2007.
The Commission authorisation should be limited to the varieties included in the list of Finnish varieties which are produced solely in Finland.
Odobritev Komisije mora biti omejena na sorte, vključene na seznam finskih sort, ki se pridelujejo samo na Finskem.
Provision should be made for the Commission to be informed of the measures taken by Finland to comply with the limits laid down in this Decision.
Zagotoviti je treba, da se Komisija obvešča o ukrepih, ki jih Finska sprejme za upoštevanje omejitev, določenih v tej odločbi.
The measures provided for in this Decision are in accordance with the opinion of the Management Committee for the Common Organisation of Agricultural Markets,
Ukrepi iz te odločbe so skladni z mnenjem Upravljalnega odbora za skupno ureditev kmetijskih trgov –
Finland is authorised, from 1 January 2009 to 31 December 2009, to grant aid to growers established on its territory producing certified seeds and certified cereal seed referred to in the Annex, within the limits of the amounts laid down in that Annex.
Finski se dovoli, da od 1. januarja 2009 do 31. decembra 2009 odobri pomoč pridelovalcem s sedežem na njenem ozemlju, ki pridelujejo certificirana semena in certificirana semena žit iz Priloge, v okviru zneskov iz navedene priloge.
Finland shall send to the Commission a list of the certified varieties concerned and any amendment thereto and inform it of the areas and quantities of seeds and cereal seed for which the aid is granted.
Finska pošlje Komisiji seznam zadevnih certificiranih sort in vse spremembe tega seznama ter jo obvesti o območjih in količinah semen ter semen žit, za katere se pomoč odobri.
OJ L 30, 31.1.2009, p. 16.
UL L 30, 31.1.2009, str. 16.
Eligible area under certified Gramineae (grass) and Leguminosae (legumes) seeds of species listed in Annex XIII to Regulation (EC) No 73/2009 with the exception of Phleum pratense L. (Timothy).
Upravičena območja območje, zasajeno s certificiranimi semeni sort Gramineae (trave) in Leguminosae (stročnice) iz Priloge XIII k Uredbi (ES) št. 73/2009, razen Phleum pratense L. (mačji rep).
Eligible area under certified seed of wheat, oats, barley and rye.
Upravičena območja območje, zasajeno s certificiranimi semeni pšenice, ovsa, ječmena in rži
authorising the placing on the market of lycopene as novel food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council
o odobritvi dajanja na trg likopena kot nove živilske sestavine v skladu z Uredbo (ES) št. 258/97 Evropskega parlamenta in Sveta
(notified under document number C(2009) 3149)
(notificirano pod dokumentarno številko C(2009) 3149)
On 18 July 2008 the company DSM Nutritional Products Ltd. made a request to the competent authorities of Ireland to place synthetic lycopene on the market as a novel food ingredient; on 6 October 2008 the competent food assessment body of Ireland issued its initial assessment report.
Družba DSM Nutritional Products Ltd. je 18. julija 2008 vložila zahtevek pri pristojnih organih Irske za dajanje sintetičnega likopena na trg kot nove živilske sestavine; pristojni organ Irske za ocenjevanje živil je 6. oktobra 2008 izdal poročilo o začetni oceni.
In that report it came to the conclusion that, in the light of other pending applications concerning lycopene, for synthetic lycopene an additional assessment is required in order to assure that an authorisation for use of the different lycopenes as novel food ingredients is granted under the same terms.
V navedenem poročilu je ugotovil, da je glede na druge nerešene zahtevke v zvezi z likopenom potrebna dodatna ocena za sintetični likopen, da se zagotovijo enaki pogoji za odobritev uporabe različnih likopenov kot novih živilskih sestavin.
The Commission forwarded the initial assessment report to all Member States on 22 October 2008.
Komisija je 22. oktobra 2008 vsem državam članicam poslala poročilo o začetni oceni.
On 4 December 2008 EFSA adopted the ‘Scientific Opinion of the Scientific Panel on dietetic Products, Nutrition and Allergies on a request from the Commission related to the safety of lycopene from Blakeslea trispora Cold Water Dispersion (CWD)’.
EFSA je 4. decembra 2008 sprejela „Znanstveno mnenje znanstvenega sveta za dietetične izdelke, prehrano in alergije na zahtevo Komisije v zvezi z varnostjo likopena, pridobljenega iz glive Blakeslea trispora z disperzijo v hladni vodi“.
EFSA also concluded that the consumption of lycopene by the average user will stay below the Acceptable Daily Intake (ADI), but that some users of lycopene may exceed the ADI.
EFSA je prav tako ugotovila, da bo povprečni uporabnik sicer užival likopen pod povprečnim dnevnim vnosom, nekateri uporabniki likopena pa sprejemljivi dnevni vnos lahko presežejo.
Particular attention should be given to the collection of data regarding levels of lycopene in breakfast cereals.
Posebno pozornost je treba nameniti zbiranju podatkov v zvezi z ravnmi likopena v žitnih kosmičih za zajtrk.
Synthetic lycopene, hereinafter called the product, as specified in Annex I may be placed on the market in the Community as a novel food ingredient to be used in the foods listed in Annex II.
Sintetični likopen (v nadaljnjem besedilu „proizvod“), kot je opredeljen v Prilogi I, se lahko da na trg v Skupnosti kot nova živilska sestavina za uporabo v živilih iz Priloge II.
The designation of the novel food ingredient authorised by this Decision on the labelling of the foodstuff containing it shall be ‘lycopene’.
Oznaka nove živilske sestavine na živilih, odobrena s to odločbo, je „likopen“.
The company DSM Nutritional Products Ltd shall establish a monitoring programme accompanying the marketing of the product.
Družba DSM Nutritional Products Ltd. hkrati s trženjem proizvoda vzpostavi program za spremljanje.
In the light of new information and a report of EFSA, at the latest in the year 2014 the use of lycopene as an ingredient to foods shall be reviewed.
Glede na nove informacije in poročilo EFSA se uporaba likopena kot živilske sestavine pregleda najpozneje do leta 2014.
This Decision is addressed to DSM Nutritional Products Ltd, Wurmis 576, CH – 4363 Kaiseraugst, Switzerland
Ta odločba je naslovljena na DSM Nutritional Products Ltd., Wurmis 576, CH-4363 Kaiseraugst, Švica
Synthetic lycopene consists of ≥ 96 % lycopene and minor quantities of other related carotenoid components.
Sintetični likopense sestoji iz ≥ 96 % likopena in manjših količin drugih povezanih karotenoidnih sestavin.
Post launch monitoring of synthetic lycopene
Spremljanje sintetičnega likopena po uvedbi na trg
Quantities of synthetic lycopene provided by DSM Nutritional Products Ltd. to their customers for the production of final food products to be placed on the market in the European Union.
Količine sintetičnega likopena, ki jih DSM Nutritional Products Ltd. zagotovi svojim strankam za proizvodnjo končnih živil, ki se dajo na trg v Evropski uniji.
Where appropriate and available to DSM Nutritional Products Ltd. also the same information on intakes of lycopene used as food colour should be reported.
Sporočiti je treba tudi iste informacije o vnosu likopena, uporabljenega kot živilsko barvilo, kadar je to ustrezno in so te informacije na voljo družbi DSM Nutritional Products Ltd.
Where available, DSM Nutritional Products Ltd. shall provide new scientific information for a reconsideration of the maximum safe intake levels of lycopene.
Družba DSM Nutritional Products Ltd. zagotovi nove znanstvene informacije za ponovno preučitev najvišje varne vrednosti vnosa likopena, kadar so takšne informacije na voljo.
Based on the collected and reported information above, DSM Nutritional Products Ltd. shall carry out an updated intake assessment.
Družba DSM Nutritional Products Ltd. na podlagi navedenih zbranih in sporočenih informacij znova oceni vrednosti vnosa.
(notified under document number C(2009) 3517)
(notificirano pod dokumentarno številko C(2009) 3517)
Having regard to Decision No 2119/98/EC of the European Parliament and of the Council of 24 September 1998 setting up a network for the epidemiological surveillance and control of communicable diseases in the Community [1], and in particular Article 3(c) thereof,
Ob upoštevanju Odločbe št. 2119/98/ES Evropskega parlamenta in Sveta z dne 24. septembra 1998 o vzpostavitvi mreže epidemiološkega spremljanja in obvladovanja nalezljivih bolezni v Skupnosti [1] ter zlasti člena 3(c) Odločbe,
According to point 2.1 of Annex I to Commission Decision 2000/96/EC of 22 December 1999 on the communicable diseases to be progressively covered by the Community network under Decision No 2119/98/EC of the European Parliament and of the Council [2], ‘diseases preventable by vaccination’, including ‘influenza’, are covered by epidemiological surveillance in the Community network pursuant to Decision No 2119/98/EC.
V skladu s točko 2.1 Priloge I k Odločbi Komisije 2000/96/ES z dne 22. decembra 1999 o nalezljivih boleznih, ki jih bo po Odločbi št. 2119/98/ES Evropskega parlamenta in Sveta postopoma zajela mreža Skupnosti [2], se bo za „bolezni, ki se preprečujejo s cepljenjem“, vključno z „gripo“, izvajalo epidemiološko spremljanje v mreži Skupnosti v skladu z Odločbo št. 2119/98/ES.
According to Article 2 of Commission Decision 2002/253/EC of 19 March 2002 laying down case definitions for reporting communicable diseases to the Community network under Decision No 2119/98/EC of the European Parliament and of the Council [3], the case definitions laid down in Annex to that Decision should be updated to the extent necessary on the basis of the latest scientific data.
V skladu s členom 2 Odločbe Komisije 2002/253/ES z dne 19. marca 2002 o opredelitvi primerov nalezljivih bolezni za poročanje mreži Skupnosti v skladu z Odločbo št. 2119/98/ES Evropskega parlamenta in Sveta [3] je treba opredelitev primerov iz Priloge k navedeni odločbi posodobiti v taki meri, kot je potrebno na podlagi najnovejših znanstvenih podatkov.
Several cases of a novel influenza virus have been reported in North America and more recently in several Member States.
Več primerov novega virusa gripe je bilo sporočenih v Severni Ameriki in pred kratkim v več državah članicah.
This virus is one of the multiple forms that can take the disease ‘influenza’, listed in Annex I to Decision 2000/96/EC.
Ta virus je ena od mnogovrstnih oblik, ki lahko povzroči bolezen „gripo“, navedeno v Prilogi I k Odločbi 2000/96/ES.
However, given that this new virus poses a risk of a pandemic influenza and requires an immediate coordination between the Community and the national competent authorities, it is necessary to provide for a specific case definition differentiating it from the more general case definition of influenza, that will enable the national competent authorities to communicate relevant information to the Community network pursuant to Article 4 of Decision No 2119/98/EC.
Vendar je treba zaradi tveganja tega novega virusa za pandemično gripo in potrebe po takojšnjem usklajevanju med Skupnostjo in nacionalnimi pristojnimi organi oblikovati posebno opredelitev primera, ki se bo razlikovala od splošnejše opredelitve primera gripe, kar bo omogočilo nacionalnim pristojnim organom, da sporočajo ustrezne informacije v mrežo Skupnosti v skladu s členom 4 Odločbe št. 2119/98/ES.
In accordance with Article 9 of the Regulation (EC) No 851/2004 of the European Parliament and of the Council of 21 April 2004 establishing a European Centre for disease prevention and control [4] (ECDC), the ECDC provided, at the request of the Commission, a technical document on the case definition for this communicable disease assisting the Commission and Member States in the development of intervention strategies in the field of surveillance and response.
V skladu s členom 9 Uredbe (ES) št. 851/2004 Evropskega parlamenta in Sveta z dne 21. aprila 2004 o ustanovitvi Evropskega centra za preprečevanje in obvladovanje bolezni [4] (ECDC) je ECDC na zahtevo Komisije pripravil tehnični dokument o opredelitvi primera za to prenosljivo bolezen v pomoč Komisiji in državam članicam pri pripravi intervencijskih strategij na področju nadzora in odziva.
The case definitions listed in the Annex to Decision 2002/253/EC should be updated on the basis of this contribution.
Opredelitve primerov iz Priloge k Odločbi 2002/253/ES je treba posodobiti na podlagi tega prispevka.
The measures provided for in this Decision are in accordance with the opinion of the Committee set up by Article 7 of Decision No 2119/98/EC,
Ukrepi, predvideni s to odločbo, so v skladu z mnenjem Odbora, ustanovljenega s členom 7 Odločbe št. 2119/98/ES –
The Annex to Decision 2002/253/EC is completed by the additional case definition contained in the Annex to the present Decision.
Priloga k Odločbi 2002/253/ES se dopolni z dodatno opredelitvijo primera iz Priloge k sedanji odločbi.
The following wording is inserted in the Annex to Decision 2002/253/EC:
V Prilogo k Odločbi 2002/253/ES se vstavi naslednje besedilo:
‘NOVEL INFLUENZA VIRUS A(H1N1) (THE SO-CALLED SWINE INFLUENZA VIRUS A(H1N1) AND MEXICAN INFLUENZA VIRUS)Clinical criteria
„NOVI VIRUS GRIPE A(H1N1) (TAKO IMENOVANI VIRUS PRAŠIČJE GRIPE A(H1N1) IN VIRUS MEHIŠKE GRIPE)Klinična merila
Any person with one of the following three:
Vsaka oseba z enim od naslednjih treh znakov:
fever > 38 °C AND signs and symptoms of acute respiratory infection,
vročina nad 38 °C TER znaki in simptomi akutne dihalne okužbe,
pneumonia (severe respiratory illness),
pljučnica (resna dihalna bolezen),
death from an unexplained acute respiratory illness.
smrt zaradi neznane akutne dihalne bolezni.
At least one of the following tests:
Vsaj eden od naslednjih testov:
viral culture (requiring BSL 3 facilities),
virusna kultura (zahtevani prostori 3. stopnje biološke varnosti),
four-fold rise in novel influenza virus A(H1N1) specific neutralising antibodies (implies the need for paired sera, from acute phase illness and then at convalescent stage 10-14 days later minimum).
štirikratno povečanje specifičnih protiteles, ki nevtralizirajo novi virus gripe A(H1N1) (vključuje potrebo po parnih serumih, od akutne faze bolezni do stopnje okrevanja vsaj 10–14 dni pozneje).
At least one of the following three in the seven days before disease onset:
Vsaj eno od naslednjih treh meril v 7 dneh pred začetkom bolezni:
a person who was a close contact to a confirmed case of novel influenza A(H1N1) virus infection while the case was ill,
oseba, ki je bila v tesnem stiku s potrjenim primerom okužbe z novim virusom gripe A(H1N1), ko je bil primer bolan,
a person who has travelled to an area where sustained human-to-human transmission of novel influenza A(H1N1) is documented,
oseba, ki je potovala na območje, na katerem je evidentiran nepretrgan prenos nove gripe A(H1N1) med ljudmi,
a person working in a laboratory where samples of the novel influenza A(H1N1) virus are tested.
oseba, ki dela v laboratoriju, v katerem se testirajo vzorci novega virusa gripe A(H1N1).
Case classification
Uvrstitev primera
Case under investigation
Primer med preiskavo
Any person meeting the clinical and epidemiological criteria.
Vsaka oseba, ki ustreza kliničnim in epidemiološkim merilom.
Any person meeting the clinical AND epidemiological criteria AND with a laboratory result showing positive influenza A infection of an unsubtypable type.
Vsaka oseba, ki ustreza kliničnim IN epidemiološkim merilom IN je okužena z virusom gripe A nekategoriziranega tipa.
Any person meeting the laboratory criteria for confirmation.
Vsaka oseba, ki ustreza laboratorijskim merilom za potrditev.
The name will be changed in line with the definition provided by the World Health Organisation.’.
Ime bo spremenjeno v skladu z opredelitvijo Svetovne zdravstvene organizacije.“
on the measure (C 33/07 (ex N 339/06 and N 729/06)) which Germany is planning to implement through the IBG Beteiligungsgesellschaft Sachsen-Anhalt mbH
o ukrepu C 33/07 (ex N 339/06 in N 729/06), ki ga namerava Nemčija izvajati prek sklada IBG Beteiligungsgesellschaft Sachsen-Anhalt mbH
(notified under document number C(2008) 5581)
(notificirano pod dokumentarno številko C(2008) 5581)
Having called on interested parties to submit their comments pursuant to those provisions [1],
po pozivu vsem zainteresiranim stranem, naj predložijo svoje pripombe v skladu z navedenimi členi [1],
Having regard to those comments,
in ob upoštevanju teh pripomb,
By letter dated 30 May 2006, received by the Commission on the same day, the German authorities notified the Commission under Article 88(3) of the EC Treaty of the first part of the measure, which the Commission registered as State aid case N 339/06.
Z dopisom z dne 30. maja 2006, ki ga je Komisija prejela istega dne, so nemški organi v skladu s členom 88(3) Pogodbe ES obvestili Komisijo o prvem delu ukrepa, ki ga je Komisija registrirala kot državno pomoč, zadeva N 339/06.
By letter dated 22 June 2006, the Commission requested additional information.
Komisija je z dopisom z dne 22. junija 2006 zahtevala dodatne informacije.
By letter dated 9 November 2006, received by the Commission on the same day, the German authorities notified the second part of the measure, which the Commission registered as State aid case N 729/06.
Z dopisom z dne 9. novembra 2006, ki ga je Komisija prejela istega dne, so nemški organi obvestili Komisijo o drugem delu ukrepa, ki ga je Komisija registrirala kot državno pomoč, zadeva N 729/06.
Owing to the overlap between the two notifications (N 339/06 and N 729/06), in a letter dated 6 December 2006 the Commission proposed to merge the cases and treat all correspondence as being relating to both, and also asked for additional information relating to both cases.
Zaradi prekrivanja med obema obvestiloma (N 339/06 in N 729/06) je v dopisu z dne 6. decembra 2006 Komisija predlagala, da se zadevi združita in se vsi dopisi obravnavajo kot dopisi, ki zadevajo obe zadevi, ter je zahtevala tudi dodatne informacije v zvezi z obema zadevama.
The German authorities replied by letter dated 23 January 2007.
Nemški organi so odgovorili z dopisom z dne 23. januarja 2007.
The Commission requested further information on 28 February 2007.
Komisija je 28. februarja 2007 zahtevala dodatne informacije.
Following an extension of the deadline, the German authorities replied by letter dated 29 June 2007.
Po podaljšanju roka so nemški organi odgovorili z dopisom z dne 29. junija 2007.
By letter dated 30 August 2007, the Commission informed Germany that it had decided to initiate the procedure laid down in Article 88(2) of the EC Treaty in respect of the aid (hereinafter the opening decision).
Komisija je z dopisom z dne 30. avgusta 2007 obvestila Nemčijo o odločitvi za sprožitev postopka iz člena 88(2) Pogodbe ES v zvezi s pomočjo (v nadaljnjem besedilu: odločitev o sprožitvi postopka).
The opening decision was published in the Official Journal of the European Union [2].
Odločitev o sprožitvi postopka je bila objavljena v Uradnem listu Evropske unije [2].
The Commission called on the German authorities and interested parties to submit their comments.
Komisija je pozvala nemške organe in zainteresirane strani, da predložijo svoje pripombe.
The Commission requested further information by letter dated 18 April 2008 and by e-mails dated 28 April 2008 and 11 June 2008.
Komisija je zahtevala dodatne informacije z dopisom z dne 18. aprila 2008 ter z elektronsko pošto z dne 28. aprila 2008 in 11. junija 2008.
The German authorities submitted additional information by letter dated 5 June 2008 and e-mail dated 13 June 2008.
Nemški organi so predložili dodatne informacije z dopisom z dne 5. junija 2008 in z elektronsko pošto z dne 13. junija 2008.
The IBG Fund is a public venture capital fund, established and funded by the Land of Saxony-Anhalt.
Sklad IBG je javni sklad tveganega kapitala, ki ga je ustanovila in ga financira dežela Saška-Anhalt.
The objective of the IBG Fund is to provide risk capital to technology-oriented innovative SMEs in Saxony-Anhalt in their early and growth stages of development.
Cilj sklada IBG je zagotavljati tvegani kapital za tehnološka inovativna mala in srednje velika podjetja v deželi Saška-Anhalt na začetni stopnji njihovega razvoja ter med njihovo rastjo.
Saxony-Anhalt is a region eligible for assistance under Article 87(3)(a) EC Treaty [3].
Dežela Saška-Anhalt je regija, ki je upravičena do pomoči na podlagi člena 87(3)(a) Pogodbe ES [3].
Since 1 July 2007, the IBG Fund has been managed by the management company Goodvent Beteiligungsmanagement GmbH & Co. KG (hereinafter the Fund manager), selected in an open and non-discriminatory public tender procedure.
Od 1. julija 2007 sklad IBG upravlja družba za upravljanje GOODVENT Beteiligungsmanagement GmbH & Co. KG (v nadaljnjem besedilu: upravljavec sklada), ki je bila izbrana na odprtem in nediskriminatornem javnem razpisu.
The IBG Fund provides the following investments:
Sklad IBG zagotavlja naslednje naložbe:
ordinary equity holdings of up to EUR 1,5 million per SME per 12-month period, with at least 30 % of the funding being provided by private independent investors on the same terms as the IBG Fund;
navadne deleže v lastniškem kapitalu do 1,5 milijona EUR na malo ali srednje veliko podjetje za dvanajstmesečno obdobje, pri čemer najmanj 30 % finančnih sredstev zagotovijo zasebni neodvisni vlagatelji pod enakimi pogoji kot sklad IBG;
ordinary equity holdings (offene Beteiligungen) of up to EUR 10 million per SME, including conversion options, such as convertible bonds (Wandelanleihen) and bonds with warrants (Optionsanleihen), effected with private investors in equal amounts, on the same terms and with the same risks (pari passu);
navadne deleže v lastniškem kapitalu (offene Beteiligungen) do 10 milijonov EUR na malo ali srednje veliko podjetje, vključno s pravicami do zamenjave, kot so zamenljive obveznice (Wandelanleihen) in obveznice z delniško nakupno opcijo (Optionsanleihen), ki jih v enakih zneskih izvajajo zasebni investitorji pod enakimi pogoji in z enakim tveganjem („pari passu“);